GeneticTechnologies BREVAGen Brustkrebsrisiko Test
| Neuester,
letzter geles. Beitrag
Seiten:
Übersicht Alle 1 2 3
 Zurück
Weiter
Antwort einfügen
|
Hot-Stocks-Forum |
|
Das Seminar über BREVAGen und Brustkrebs Risikobewertung findet am Freitag, 17 August, 2012 von 12.30 Uhr bis 02.00 Uhr in The Woodlands Institut für Gesundheit und Wellness in 26110 Oak Ridge Drive, The Woodlands, Texas. Alle Interessierten, die mehr über Brustgesundheit und BREVAGen ist herzlich eingeladen.
Local Physician One Of The First In Nation To Use New Breast Cancer Predictive Risk Test
THE WOODLANDS, Texas--(BUSINESS WIRE)--Dr. Mila McManus of The Woodlands Institute for Health and Wellness, one of the first physicians in the nation to make the BREVAGen™ predictive risk test available to her patients, is conducting a free community seminar on August 17, 2012 to introduce BREVAGen and discuss its importance in breast cancer risk assessment. Clinically validated, BREVAGen is the latest advance in assessing a woman’s unique risk of developing non-familial or sporadic breast cancer, which accounts for 70 to 80 percent of all breast cancer cases.
...wie man sieht,der Test startet erst jetzt so richtig,immerr noch Zeit in Genetic Techn. zu investieren!
so long!
TM
MELBOURNE, AUSTRALIA -- (Marketwire) -- 07/26/12 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the Laboratory Field Services Unit of the California Department of Public Health (CDPH) has granted a license to the Company's Australian-based laboratory. BREVAGen™ may now be offered forhe State of C sale into talifornia.
Based solely on incidence rates, California represents approximately 11% of the United States' total breast cancer incidents, with over 25,000 new cases of breast cancer diagnosed annually. (ACS Breast Cancer Facts & Figures 2011-12, ACS Cancer Facts & Figures 2012)
We expect Califoro be a large and significant market for BREVAGen™," said Dr. Paul MacLeman, Genetic Technologies' Chief Executive Officer. "We will be applying sales and marketing resources to drive test adoption and sales in the State in the coming weeks."
U.S. State Certification
In April 2011, Genetic Technologies successfully attained CLIA approval, allowing BREVAGen™ to be sold into 42 U.S. States (see ASX announcement dated April 27th, 2011). Following the Company's receipt of a certificate of compliance issued by the Centers for Medicare and Medicaid Services (see ASX announcement dated February 16th, 2012), the Company has submitted numerous applications for "Out of State Licensure," which allow BREVAGen™ to also be sold in Pennsylvania, Rhode Island, Nevada, Tennessee, Maryland, and now in California. The Company has also submitted a licensure application in Florida and expects to receive approval to sell BREVAGen™ in this key State shortly.
The Company has commenced serial submission of an application to submit to the New York State Department of Health, Clinical Laboratory Evaluation Program (CLEP) to offer Out of State Clinical Lab Services to New York State residents.
August 8, 2012
Genetic Technologies Receives CE Mark Approval for BREVAGen™
Melbourne, Australia; August 8, 2012: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE)
announced today that it has received European CE Mark approval for BREVAGen™, the Company’s
breast cancer risk test. The CE Mark designation will allow BREVAGen™ to be sold in the EU and
other countries that recognise the CE Mark. The initial commercial focus will be in the key markets of
France and Germany.
Breast cancer is the most common form of cancer in European women. In 2008, annual breast cancer
incidence in the European Union (EU-27) was over 330,000. This is nearly double the incidence rate in
the U.S. of just over 180,000 cases per year (cited electronically at http://globocan.iarc.fr/). Approximately 80%
of women who develop breast cancer develop non-familial or sporadic breast cancer, that is, they have
little or no family history of the disease.
“The achievement of CE Mark for our flagship BREVAGen™ product is a major milestone for the
Company,” stated Dr. Paul MacLeman, CEO of Genetic Technologies. “Given the significant incidence
rate of breast cancer in the EU, there is a critical need for enhanced risk assessment tools, leading to
improved preventative management and surveillance.”
BREVAGen™ uses a novel approach to non-familial breast cancer risk assessment, combining validated
breast cancer susceptibility genetic markers with a patient’s individual clinical risk factors to yield an
Another stock that’s quickly moving within range of triggering a near-term breakout trade is Genetic Technologies (GENE), which provides genetic testing services. This stock is off to a strong start in 2013, with shares up sharply by 24%.
If you look at the chart for Genetic Technologies, you’ll notice that this stock has been uptrending strong for the last two months, with shares moving higher from its low of $2.10 to its recent high of $2.90 a share. During that uptrend, shares of GENE have been consistently making higher lows and higher highs, which is bullish technical price action. That move has quickly pushed shares of GENE within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in GENE if it manages to break out above some near-term overhead resistance levels at $2.75 to $2.80 a share and then once it takes out more resistance at $2.90 to its 200-day at $3.14 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 38,979 shares. If that breakout triggers soon, then GENE will set up to re-test or possibly take its next major overhead resistance levels at $3.40 to $3.80 a share. Any high-volume move above those levels will then put $3.95 to $4.22 into range for shares of GENE.
Traders can look to buy GENE off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $2.47 a share or around more support at $2.36 a share. One can also buy GENE off strength once it clears those breakout levels with volume and then simply use a stop that sits right below its 50-day at $2.47 a share. I would add to either position once GENE clears its 200-day at $3.14 a share with heavy upside volume.
|
